|
|
- Todd Lawrence
- 5 years ago
- Views:
Transcription
1
2
3
4
5
6 Global mortality from viral hepatitis (Cooke et al)
7 Changing Patterns of the Causes of Death in a Swiss Cohort (SHCS) SHCS is a prospective observational cohort Characteristics of participants that died from deaths/9,053 participants (5.1%) Causes of Death in Participants in the Swiss HIV Cohort Study in 3 different Time Periods, and in the Swiss Population in 2007 Proportion 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Swiss 2007 AIDS Non-AIDS malignancy Non-AIDS infection Liver Heart CNS Kidney Intestine/pancreas Lung Suicide Substance use Accident/homicide Other UnKnown Years of Death of HIV+ Persons Versus Swiss Population Ruppik M, et al. 18th CROI; Boston, MA; February 27-March 2, Abst. 789.
8
9 Summary of EASL and AASLD 2014/ % SVR24 (%)
10 INTEGRATED SUMMARY OF RESULTS: SVR12 TREATMENT NAIVE PATIENTS HCV/HIV coinfected HCV monoinfected All 100% 94,0% 94,8% 94,5% 96,6% 90,5% 94,1% 91,8% 94,2% 94,1% 75% SVR, % 50% 25% 0% 233 / / / /29 95 / / / /609 EBR/GZR EBR/GZR + RBV Total 834 /886 *Primary endpoint: SVR12 (HCV RNA <15 IU/mL)
11 INTEGRATED SUMMARY OF RESULTS: SVR12 TREATMENT EXPERIENCED PATIENTS HCV/HIV coinfected HCV monoinfected All 100% 100,0% 91,5% 100,0% 100,0% 91,8% 94,8% 94,9% 83,3% 93,4% 97,8% 97,8% 95,2% 93,9% 94,4% 94,5% 75% SVR, % 50% 210 /218* 210 /217* 139 / /44 27 /28 25% 0% 6/6 140 / /159 GZR/EBR 12 weeks 5/5 199 / /215 GZR/EBR+RBV 12 weeks 5/6 123 / /137 GZR/EBR weeks* 4/4 132 / /139 GZR/EBR+RBV weeks* 20 / /629 Total 614 /650 *HCV/HIV coinfected patients treated for 16 weeks and HCV monoinfected patients treated for 18 weeks
12 Do HIV+ respond differently to mono-infected patients? Karageorgopoulos, World J Hepatol, 2015; 7: 1936
13
14 Baseline characteristics GECCO Cohort: ledipasvir/sofosbuvir 8 weeks Overall (n=148) HCV (n=120) HIV-HCV (n=28) Male sex, n (%) 72 (49) 49 (41) 23 (82) <0.001 Median age [years] (IQR) 52 (44 58) 54 (45 62) 50 (42 62) 0.01 Transmission IVDU/MSM/blood, n (%) 46(31)/15(10)/ 36(24) 39(33)/1(1)/ 39(33) 7(25)/14(50)/ 0 p <0.01 HCV genotype 1/4, n (%) 144(97)/3(2) 120 (100) 24(86)/3(11) <0.001 Median HCV viral load [IU/mL] (IQR) 8.1x10 5 (2.5x x10 6 ) 9x10 5 (3.4x x10 6 ) 4.9x10 5 (8x x10 5 ) Median ALT [U/L] (IQR) 56 (37 89) 53 (36 80) 78 (49 166) <0.01 Prior HCV treatment, n (%) 26 (18) 22 (18) 4 (14) ns Fibroscan >12.5kPa or APRI >2, n (%) 5 (3) 3 (3) 2 (7) HIV coinfection, n (%) 28 (19) 0 (0) 28 (100) Median CD4 cell count [/mm 3 ] (IQR) 531 ( ) NA 531 ( ) 8 weeks of LDV/SOF is not within label for cirrhosis, GT4 or prior treatment Ingiliz P et al. EACS Abstract PS7/5 0.01
15 Efficacy: SVR4 rates Sofosbuvir/ledipasvir for 8 weeks in real-life, SVR 4: 99% SVR 4, % /105 14/14 4/4 1/1 16/16 10/10 Overall HIV-HCV F4 GT 4 pretreated High VL Metavir F4 defined as APRI > 2 OR Fibroscan > 12.5kPa, high VL load defined as > 2mio IU/ml (Abbott PCR) or 6 mio IU/ml (Roche PCR), prior treatment was interferon-based (in one case with sofosbuvir) 8 weeks of LDV/SOF is not within label for cirrhosis, GT4 or prior treatment Ingiliz P et al. EACS Abstract PS7/5
16 Efficacy: SVR12 rates Sofosbuvir/ledipasvir for 8 weeks in real-life, SVR 12: 98.5% SVR12, % /70 7/7 3/3 12/12 9/9 Overall HIV-HCV F4 pretreated High VL Metavir F4 defined as APRI > 2 OR Fibroscan > 12.5kPa, high VL load defined as > 2mio IU/ml (Abbott PCR) or 6 mio IU/ml (Roche PCR), pretreatment was interferon-based (in one case with sofosbuvir) 8 weeks of LDV/SOF is not within label for cirrhosis, GT4 or prior treatment Ingiliz P et al. EACS Abstract PS7/5
17 HIV is a special population?
18 Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3) or cirrhosis (F4) including compensated cirrhosis HIV coinfection, HBV coinfection Indication for liver transplantation HCV recurrence after transplantation Extra-hepatic manifestations Debilitating fatigue Risk of transmitting HCV Justified Deferred Not recommended Pts with moderate fibrosis (F2) Pts with no or mild (F0-F1) disease and no extra-hepatic manifestations Pts with limited life expectancy due to non-liver comorbdities EASL Guidelines
19
20
21
22 Increased risk of cirrhosis and ESLD due to HIV/HCV co-infection Histologic Cirrhosis Relative Risk Decompensated Liver Disease Relative Risk Makris (UK) Soto (Spain) Pol (France) Benhamou (France) Combined Eyster (USA) Telfer (UK) Makris (UK) Lesens (Canada) Combined HCV Only HIV/HCV HCV Only HIV/HCV Graham CS, et al. Clin Infect Dis. 2001;33:
23 HIV/HCV co-infection may result in multi-systemic disorders Global cognitive impairment Cognitive-motor impairment Dementia Peripheral neuropathy Neurologic disease Cerebrovascular disease Acute myocardial infarction Opportunistic infections Wasting syndrome Proteinuria Acute renal failure Chronic kidney disease Cardiovascular HIV disease progression Kidney disease Immune activation HIV/HCV Immune dysregulation Metabolic disorders Liver disease GI tract Diabetes mellitus Insulin resistance Steatosis Fibrosis Cirrhosis End-stage liver disease Liver-related death Microbial translocation Osteonecrosis Osteoporosis Bone fracture Bone disorders CD4 apoptosis Abnormal T-cell responses and cytokine production Cytotoxic T-cell accumulation in liver CD4 recovery post-haart Severe immunodeficiency GI: gastrointestinal; HAART: highly active antiretroviral therapy Operskalski E, et al. Curr HIV/AIDS Rep. 2011;8:12-22.
24
25 DIABETES
26
27 27
28
29
30 Drug drug interactions between HIV drugs and DAAs Key (accessed October 2015)
31 Summary of EASL and AASLD 2014/ % SVR24 (%)
32
33 Figure 2. Treatment Cascade for People with Chronic Hepatitis C Virus (HCV) Infection, Prevalence Estimates with 95% Confidence Intervals. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE 9(7): e doi: /journal.pone
34 Figure 2. Treatment Cascade for People with Chronic Hepatitis C Virus (HCV) Infection, Prevalence Estimates with 95% Confidence Intervals.?100% Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE 9(7): e doi: /journal.pone
35 Figure 2. Treatment Cascade for People with Chronic Hepatitis C Virus (HCV) Infection, Prevalence Estimates with 95% Confidence Intervals.?100% Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE 9(7): e doi: /journal.pone
36 Figure 2. Treatment Cascade for People with Chronic Hepatitis C Virus (HCV) Infection, Prevalence Estimates with 95% Confidence Intervals.?5% DAA Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE 9(7): e doi: /journal.pone
37 50
38 New diagnosed HIV-positive MSM HCV uninfected (Ab-/RNA-) Susceptible treatmentnaive (Ab+/RNA-) Infection Acute HCV, spontaneous clearance (undiagnosed + diagnosed) Early HCV (<1 yr from infection), undiagnosed Early HCV (<1 yr from infection), Diagnosed New diagnosed HIV-positive MSM Chronic HCV (>1 yr from infection), undiagnosed Chronic HCV (>1 yr from infection), Diagnosed yr 1 Re-infection Early ( acute ) treatment Chronic, Diag yr 2+ Susceptible, treatmentexperienced Treatment failure Chronic treatment Also stratify by treatment naïve, IFN-experienced, DAA-experienced and low/high risk HIV and non-hiv death occurs from all states
39
40 Acute HCV among HIV+ MSM Canada: ~30 cases Prevalence chronic HCV/HIV 19%: USA: 55 cases Prevalence chronic HCV/HIV 15 30%: Lebanon: 1 case Prevalence chronic HCV/HIV 49%: Europe: 1068 cases Prevalence chronic HCV/HIV 25%: UK 552 -Germany 157 -France 126 -Netherlands 97 -Belgium 69 -Swiss 23 -Italy 21 -Denmark 13 -Spain ~8 Taiwan: 28 cases Prevalence chronic HCV/HIV 5%: Australia: 47 cases Prevalence chronic HCV/HIV < 1%:
41 Social site and apps have made finding Chem-Sex easy and anonymous IDU or slamming has become more common place
42 The popularity of bareback sites
43
44
45 Results HCV detected in 20 (47%) of 43 specimens 2 invalid Median rectal VL 2.92 log10 IU/mL High correlation between magnitude of blood and rectal HCV VL Rectal HCV VL (log 10 IU/mL) 1 0 (r = 0.689, p < 0.001) Serum HCV VL (log 10 IU/mL) 8
46 No historic treatment in UK HCV chronic (RNA+) prevalence among HIV-diagnosed MSM(%) CHRONIC PREVALENCE No historic treatment HCV primary incidence among HIV-diagnosed MSM (/100py) 2,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 PRIMARY INCIDENCE Martin NK et al, under review
47 HCV chronic (RNA+) prevalence among HIV-diagnosed MSM(%) Current treatment rate with DAAs (90% SVR) from 2015 CHRONIC PREVALENCE Current treatment with DAAs HCV primary incidence among HIV-diagnosed MSM (/100py) 2,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 PRIMARY INCIDENCE Current treatment with DAAs Martin NK et al, under review
48 HCV chronic (RNA+) prevalence among HIV-diagnosed MSM(%) Scale-up treatment for recent (80%) diagnoses with DAAs from 2015 CHRONIC PREVALENCE Scale-up treatment for recent diagnoses HCV primary incidence among HIV-diagnosed MSM (/100py) 2,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 PRIMARY INCIDENCE Scale-up treatment for recent diagnoses Martin NK et al, under review
49 HCV chronic (RNA+) prevalence among HIV-diagnosed MSM(%) Scale-up treatment for recent (80%) & nonrecent diagnoses (20%/yr) with DAAs from 2015 CHRONIC PREVALENCE Scale-up treatment for recent AND nonrecent diagnoses HCV primary incidence among HIV-diagnosed MSM (/100py) 2,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 PRIMARY INCIDENCE Scale-up treatment for recent AND nonrecent diagnoses Martin NK et al, under review
50
51 Survival estimates Proportion free from reinfection % CI Previous spontaneous clearance 95% CI Previous SVR Time at risk (years) Martin TC et al. AIDS 2013;27:2551 7
52 HCV re-infection incidence among HIV MSM changes over time 25 Re-infection incidence per 100py
53
54 Scale-up treatment for recent (80%) & nonrecent diagnoses (20%/yr) with DAAs and 20% behavioural risk reduction from 2015 HCV chronic (RNA+) prevalence among HIV-diagnosed MSM(%) CHRONIC PREVALENCE Scale-up treatment AND behaviour change HCV primary incidence among HIV-diagnosed MSM (/100py) 2,0 1,8 1,6 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 PRIMARY INCIDENCE Scale-up treatment AND behaviour change Martin NK et al, under review
55
56 HCV risk among HIV- individuals 44 cases AHC identified by NEAT criteria 5 HCV Ab negative < 1 year 11 significant ALT rise 18 clinically diagnosed with AHC Mc Faul ICAAC 2014 McFaul K, et al. ICAAC 2014; Abstract V-676.
57
58 whocares
School of Social and Community Medicine, University of Bristol Division of Global Public Health, UC San Diego
This work was partially supported through a research grant from Gilead Sciences. Gilead had no influence on the design, analysis and content of the study Presentation based on work by Peter Vickerman,
More informationHepatitis C: Time for Elimination?
Hepatitis C: Time for Elimination? Catherine Stedman Clinical Associate Professor of Medicine University of tago, Christchurch Gastroenterology Department, Christchurch Hospital What is hepatitis C? Hepatitis
More informationTREATMENT AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES
PLANNING FOR TREATMENT AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES ADVANCES IN HEP C TREATMENT LEARN MORE ABOUT HEP C There s never been a better time to treat Hep C. Recent scientific advances
More informationHealth and budget impact of combined HIV prevention. S. Vermeersch, hict L. Annemans, UGent
Health and budget impact of combined HIV prevention S. Vermeersch, hict L. Annemans, UGent Outline Context and objectives Modeling approach Model validation Results Conclusions Disclosures The study was
More informationRecent Mortality Trends and Prospects: Hong Kong and Taiwan
Recent Mortality Trends and Prospects: Hong Kong and Taiwan Edward Jow-ching Tu Wang Jian-Ping Division of Social Science HKUST, HKSAR, China soejctu@ust.hk Introduction Current mortality in Hong Kong
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationA Comparative Look at Pain Prevalence: Europe and U.S.
A Comparative Look at Pain Prevalence: Europe and U.S. Zachary Zimmer (Mount Saint Vincent University, Canada) Anna Zajacova (Western University, Canada) ADDAPT working group workshop, Pain, Pain Treatment,
More informationLeading Causes of Death in Hawaii
Leading Causes of Death in Hawaii Death Counts, Age-Adjusted Mortality Rates, and Years of Potential Life Lost for the State of Hawaii (Residents Only), by Cause of Death, by This report displays the average
More informationLeading Causes of Death in Hawaii
Leading Causes of Death in Hawaii Death Counts, Age-Adjusted Mortality Rates, and Years of Potential Life Lost for the State of Hawaii (Residents Only), by Cause of Death, by This report displays the average
More informationRio Grande County Births and Deaths 2015
Rio Grande County Births and Deaths 2015 Selected birth characteristics: County residents, 2015... 2 Selected birth characteristics by age group of mother: County residents, 2015... 3 Selected birth characteristics
More informationMolecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth Trends & Forecast to 2021
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth Trends & Forecast to 2021 Molecular
More informationWORKSHOP ON INCREASING RATES ON ORGAN DONATION -INSTITUTE OF MEDICINE-
WORKSHOP ON INCREASING RATES ON ORGAN DONATION -INSTITUTE OF MEDICINE- RAFAEL MATESANZ DIRECTOR ONT - SPAIN (SPANISH NATIONAL TRANSPLANT ORGANIZATION) UNIVERSAL PROBLEM 30 SPAIN 30 USA 20 10 20 ITALY
More informationPRE-CALCULATED PREMIUMS FOR
United Home life Insurance Company United Farm Family Life Insurance Company P.O. Box 7192 Indianapolis, Indiana 46207-7192 800-428-3001 PRE-CALCULATED PREMIUMS FOR EXPRESS ISSUE PREMIER WHOLE LIFE EXPRESS
More informationPanzyga Administration Guide
Immune Human Normal Globulin Immunoglobulin Intravenous (Human) (IVIg) Octapharma s new Intravenous Immunoglobulin (IVIG) Panzyga Administration Guide An educational service tool provided by Octapharma
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationU n i t 1. Magnitude and impact of road traffic injuries
U n i t 1 Magnitude and impact of road traffic injuries 1 WHO, 2007 Objectives Objectives By the end of this unit, the trainee should be able to: describe the global magnitude and trends of road traffic
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationTransmissible Spongiform Encephalopathies (TSE) D. Heim
Transmissible Spongiform Encephalopathies (TSE) D. Heim What are TSE? Family of diseases Neurological disease accumulation of abnormal prion protein spongiform degeneration of the brain progressive and
More informationAuthor of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently
Interview with Rehan Jalali, President, Supplement Research Foundation Author of: The Six-Pack Diet Plan: The Secrets to Getting Lean Abs and a Rock-Hard Body Permanently Background Information: According
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNew Directions in Aplastic Anemia: What is on the Horizon
Case Presentation #1 New Directions in Aplastic Anemia: What is on the Horizon Gabrielle Meyers, MD 62 y/o male, with hypertension, who presented to his PCP for evaluation of fatigue, shortness of breath
More information+ Competitive Intelligence Report: Final Expense Life 3rd Quarter 2010
+ Competitive Intelligence Report: Final Expense Life 3rd Quarter 2010 Prepared by: Bryan R. Neary FSA, MAAA Shawn idge Kiley Eisenbarth CSG Actuarial, LLC 807 North 50th Street Omaha, NE 68132 402.502.7747
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAtlanta Part A Monitoring of Quality Indictors, Chart Review N= CW Data 2 100% 58% (N=9) (N=5) N/A 7.6% 93.7% 24.
1 2 HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients: HRSA Group 1 ARV Therapy 80.0% for Pregnant N/A N/A N/A 100% 58% (N=9) (N=5) Women* CD4 T-Cell Count* 79% every 6 mos. N/A 7.6%
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationThe Canadian Tuberculosis Prevention and Control Strategy: Targeting our Efforts
The Canadian Tuberculosis Prevention and Control Strategy: Targeting our Efforts Andrea Saunders Tuberculosis Prevention and Control Public Health Agency of Canada The Global Burden of Tuberculosis 1 in
More informationHelminths: Schistosoma mansoni. Schistosoma japonicum 10/14/2009. Trematoda - non-segmented flat worms
Helminths: Trematoda - non-segmented flat worms The schistosomes: Schistosoma mansoni Schistosoma haematobium Schistosoma japonicum Schistosoma mekongi Aquatic freshwater snails are the intermediate hosts
More informationPr oject Summar y. Principal Investigators: Walter Cook, Elizabeth Williams, Fred Lindzey, and Ron Grogan. University of Wyoming
Pr oject Summar y Chronic wasting disease in white-tailed deer in Wyoming: Interaction with livestock, movement patterns, and evaluation of ante-mortem diagnostic tests Principal Investigators: Walter
More information10/14/2009. Helminths: Trematoda - non-segmented flat worms. The schistosomes: Schistosoma mansoni Schistosoma haematobium. Schistosoma mekongi
Helminths: Trematoda - non-segmented flat worms The schistosomes: Schistosoma mansoni Schistosoma haematobium Schistosoma japonicum Schistosoma mekongi 1 Japan is schistosome-free as of 1976 2 Aquatic
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationBasic values of ozone-therapy
Basic values of ozone-therapy by Dr. med. Horst Kief Presentation in Istanbul Okt 2012 Energy gain in the brakedown of fermentation compared to the energy gain in oxygen metabolism 700 600 500 k c a l
More informationThe control and eradication of Mycoplasma synoviae in Dutch commercial poultry
The control and eradication of Mycoplasma synoviae in Dutch commercial poultry W.J.M. Landman & A. Feberwee GD Animal Health, Deventer, the Netherlands X-bacillus 0.5 µm Mycoplasmas in birds About 25
More informationAN-SNAP Class allocation. There are two steps to allocating a SNAP class for each patient
AN-SNAP Class allocation There are two steps to allocating a SNAP class for each patient SNAP class allocation Step 1 1. The impairment code must be allocated. There are two over-riding rules that need
More informationAtlanta EMA Ryan White Part A Monitoring of Clinical Performance, Chart Review N= CW Data 2 100% 58% (N=9) (N=5)
1 2 HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients: HRSA Group 1 ARV Therapy 80.0% for Pregnant N/A N/A N/A 100% 58% (N=9) (N=5) Women* CD4 T-Cell Count* 79% every 6 mos. 3 Benchmarks
More informationSelf-declaration by New Zealand of its status of freedom from Equine Viral Arteritis
Self-declaration by New Zealand of its status of freedom from Equine Viral Arteritis Self-declaration submitted to the OIE on xxxx2014, by Dr Matthew Stone, Chief Veterinary Officer, Ministry for Primary
More informationAcute Mountain Sickness
Innere Medizin VII / Sportmedizin Acute Mountain Sickness Peter Bärtsch www.klinikum.uni-heidelberg.de/sportmedizin AMS: Clinical Picture Symptoms: - Headache - Loss of appetite, nausea, vomiting - Dizziness
More informationThe challenges of eliminating tuberculosis
The challenges of eliminating tuberculosis Christopher Dye World Health Organization Pre 2015: dynamics and control of TB Drug resistance as part of the TB challenge Post 2015: TB elimination and sustainable
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationQUESTIONNAIRE FOR MEMBERS OF THE PUBLIC
MAHSC Oxygen Project. Questionnaires for members of the public V1 10-12-2011 QUESTIONNAIRE FOR MEMBERS OF THE PUBLIC We would like to know what you think about oxygen therapy as a member of the public.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationDomantas Jasilionis Sustainability of life expectancy improvements in Europe. Demographic Research Centre
Domantas Jasilionis Sustainability of life expectancy improvements in Europe Demographic Research Centre INTRODUCTION AND OUTLINE Recent concerns about longevity progress Longevity divergences - and integral
More informationHazardous substances in the workplace
Overview Hazardous substances in the workplace A systematic approach to managing risks, including: - identifying hazardous substances - assessing risk - controlling risk Maintaining a safe workplace Victorian
More informationIN VITRO DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS HLC186A November 2015 Sangeetha Prabakar Project Analyst ISBN: 1-62296-178-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationFitbit s 100+ Billion Hours of Resting Heart Rate User Data Reveals Resting Heart Rate Decreases After Age 40
NEWS RELEASE Fitbit s 100+ Billion Hours of Resting Heart Rate User Data Reveals Resting Heart Rate Decreases After Age 40 2/14/2018 Fitbit analysis of millions of global users also shows U.S. and Singapore
More informationGlobal Use of Plasma-Derived Medicinal Products
Global Use of Plasma-Derived Medicinal Products Patrick Robert The Marketing Research Bureau, Inc. IPFA Workshop on Improving Access to Plasma and Plasma Products in the Southern African Region December
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationGeorgia Annual Health Status Measures 2018
Georgia Annual Health Status Measures 2018 with comparisons to the U.S. and Healthy People 2000, 2010 & 2020 objectives Prepared by the Office of Health Indicators for Planning (OHIP), Georgia Department
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationBiology Paper, CSE Style (Martin)
Biology Paper, CSE Style (Martin) Hypothermia, the Diving Reflex, and Survival Full title, writer s name, name of course, instructor s name, and date (all centered). Briana Martin Biology 281 Professor
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationGLOBAL TRENDS IN PLASMA-DERIVED MEDICINAL PRODUCTS SUPPLY AND DEMAND Patrick Robert The Marketing Research Bureau, Inc.
GLOBAL TRENDS IN PLASMA-DERIVED MEDICINAL PRODUCTS SUPPLY AND DEMAND Patrick Robert The Marketing Research Bureau, Inc. L UTILIZZO DEI MEDICINALI PLASMADERIVATI IN ITALIA Istituto Superiore di Sanità 12
More informationBuilding a Healthy Boston. BOSTON PUBLIC HEALTH COMMISSION Infectious Disease Bureau Communicable Disease Control Division
BOSTON PUBLIC HEALTH COMMISSION Infectious Disease Bureau Communicable Disease Control Division Number of cases 200 180 160 140 120 100 80 60 40 93 87 79 89 77 82 75 67 64 70 57 61 49 61 57 58 44 41 40
More informationChapter 37 (pages ): Hereditary Angioedema and Bradykinin-Mediated Angioedema Prepared by: Sarah Spriet, DO
FIT Board Review Corner May 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the Board
More informationWhat do these athletes have in common?
What do these athletes have in common? Drugs in Sport Why do athletes cheat? 1988 Olympics 100m Final Why is this photo so iconic? 1988 Olympics 100m Final First time ever 4 of the 8 finalists run under
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationPedigree Analysis of Holstein Dairy Cattle Populations
Pedigree Analysis of Holstein Dairy Cattle Populations C.Maltecca, F.Canavesi, G.Gandini, A.Bagnato. Department VSA, University of Milan, Italy ANAFI, Cremona, Italy Summary A pedigree analysis on the
More information2015 Victorian Road Trauma. Analysis of Fatalities and Serious Injuries. Updated 5 May Page 1 of 28. Commercial in Confidence
2015 Victorian Road Trauma Analysis of Fatalities and Serious Injuries Updated 5 May 2016 Page 1 of 28 Commercial in Confidence VICROADS_n3445896_2015_Victorian_Trauma_Report_- _updated_may_2016.docx 2015
More informationActive Travel & Health
Active Travel & Health Audrey de Nazelle APRIL meeting June 2017 Burden of disease from physical inactivity Coronary heart disease Type 2 diabetes Breast cancer Colon cancer All-cause mortality Global
More informationMortality Working Group
2 Mortality Working Group Chair: Paul Lewis (South Africa) Co-vice-chairs: Allen M. Klein (US) Brian Ridsdale (UK) 30 members + 31 interested persons Devoted to the world wide study of mortality Mortality
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationGreenhouse gas emissions from transport have been rising and are expected to continue to rise both in higher & lower income countries.
1 Greenhouse gas emissions from transport have been rising and are expected to continue to rise both in higher & lower income countries. Transport is seen as a hard area for mitigation 2 However, there
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal trauma, blunt, 583 584 deaths due to, 583 Agent of commission, ringside physician as, 513 Agitation/aggression, following boxing
More informationLandscape of organ donation and transplantation activity in Canada
Landscape of organ donation and transplantation activity in Canada Jagbir Gill MD MPH FRCPC Associate Professor of Medicine, UBC Vice President, CORR Board 2017 CST Fellows Symposium, September 25, 2017
More informationALBERTA CANCER REGISTRY
Cancer Care ALBERTA CANCER REGISTRY 2009 Annual Report of Cancer Statistics December 2012 ISSN: 1705-0251 Contents About The Alberta Cancer Registry... 2 Introduction... 3 Highlights... 3 Data... 3...
More informationHepatitis B surface. antigen prevalence. HepatitisB_whocdscsrlyo2002_2.pdf. Accessed 20 October, 2010.) Intermediate 2 7% High 8% Low <2%
Hepatitis B surface antigen prevalence High 8% Intermediate 2 7% Low
More informationANNUAL SUMMARY OF INFECTIOUS DISEASES OHIO 2014
OHIO DEPARTMENT OF HEALTH ANNUAL SUMMARY OF INFECTIOUS DISEASES OHIO 2014 REPORTED INCIDENCE OF SELECTED NOTIFIABLE DISEASES PREPARED AND DISTRIBUTED BY: BUREAU OF INFECTIOUS DISEASES TABLE OF CONTENTS
More informationThe Wilson and Jungner principles of screening and genetic testing
Leeds Institute of Health Sciences The Wilson and Jungner principles of screening and genetic testing Professor Darren Shickle Academic Unit of Public Health European Forum for Evidenced-based Prevention
More informationREEFTRIP.com. Medical Questionnaire Dive Medical Recreational AS Section Abbott Street, Cairns T: E:
REEFTRIP.com 100 Abbott Street, Cairns T: 07 4037 2700 E: info@reeftrip.com Medical Questionnaire Dive Medical Recreational AS4005.1 Please complete the following Section 1 1 Surname: Given Names 2 Date
More informationPhysical activity has a number of benefits
Health Policy Brief September 2018 Walking Among California Adults Susan H. Babey, Joelle Wolstein, and Allison L. Diamant SUMMARY: This policy brief describes two types of walking among California adults:
More informationPatient Information. Physician Information
Patient Information CONTINUE ONLY IF: Not currently prescribed or taking medications: Bleomycin, Disulfiram, Mafernide Acetate Do not have or suspect having: Hereditary Sperocytosis, Sickle Cell Anemia,
More informationDrug resistance surveillance: global overview and latest development
Drug resistance surveillance: global overview and latest development Matteo Zignol World Health Organization Workshop on TB prevalence surveys and TB surveillance Accra, Ghana, 29 April - 3 May 2013 Drug
More informationFlip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial
Flip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial Dr. Martin Spink, Ms. Angela Searle and Dr. Vivienne Chuter Podiatry department Faculty of Health
More informationState Level Firearm Ownership and Storage Information Informs Risk, Benefit and Public Health and Public Safety Programming
State Level Firearm Ownership and Storage Information Informs Risk, Benefit and Public Health and Public Safety Programming Why More States Should Consider This on the 2017 Behavioral Risk Factor Surveillance
More information: Accu-Sed Plus Normal & Abnormal ESR Control Kit
SECTION 1: Identification 1.1. Identification Product form Product name Product code : Mixture : Accu-Sed Plus Normal & Abnormal ESR Control Kit : DS-71002, DS-71003, DS-71004, DS-71005A, DS-71006 1.2.
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationHospital Admissions in the Northern Territory
Hospital Admissions in the Northern Territory 1976-28 www.healthynt.nt.gov.au Hospital Admissions in the Northern Territory, 1976 to 28 Shu Qin Li Sabine Pircher Steve Guthridge John Condon Jo Wright Acknowledgements
More informationGlobal NASH (Non-Alcoholic Steatohepatitis) Market: Trends, Opportunities and Forecasts ( )
Global NASH (Non-Alcoholic Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) NASH Segments By Off Label and Label Drugs By Region- US, Europe and Japan GR-MD-02 GFT 505 Market Aramchol
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationConcussion: where are we now?
Exeter Sports Medicine conference 2018 Concussion: where are we now? Dr Simon Kemp Medical Services Director, Rugby Football Union @drsimonkemp simonkemp@rfu.com Disclosures of interest Medical Services
More informationRoad Safety Attitudes and Perceptions of Pedestrians in Europe
Athens, Greece April 23-26 2012 Transport Research Arena Europe 2012 Road Safety Attitudes and Perceptions of Pedestrians in Europe E. Papadimitriou a, A. Theofilatos a, G. Yannis a, G.M. Sardi b, R. Freeman
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationEpidemiology of injuries within English youth rugby union
Epidemiology of injuries within English youth rugby union Epidemiology of injuries within English youth rugby union Executive Summary The aim of this research was to determine the rate, severity, type
More informationTalent. Motivation Training. What makes a great athlete? Data from elite athletes. Trainability Avoiding injury. In other words...
08/09/2017 Making decisions about supplement use Ron Maughan St Andrews University Scotland Seminar Targalt toidulisanditest IOC Conference on Dietary Supplements and the Elite Athlete 31. augustil kell
More informationWhat is the Role of Chest Compression Depth during Out-of-Hospital CPR?
Resuscitation Outcomes Consortium What is the Role of Chest Compression Depth during Out-of-Hospital CPR? Ian Stiell for The ROC Investigators Co-Authors Ian Stiell University of Ottawa Siobhan Everson-Stewart
More informationHCV Ag Linearity Panel Max
Linearity Max Catalogue No: LPL-HCVAg-001 The Biomex GmbH HCV Antigen Linearity Max consists of 100 s (Genotypes 1a, 1b, 2b, 2c, 3a) with each containing 1.0 ml of human plasma. This panel spans the upper
More informationEuropean Golf Statistics 2017
European Golf Statistics 2017 Leading the Business of Golf Photo by Aidan Bradley Distribution of registered golfers over the last year: Male golfers: 66% Female golfers: 25% Junior golfers: 9% Total number
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationPlasma as a Strategic Resource: perspectives and potential solutions in the public sector
Plasma as a Strategic Resource: perspectives and potential solutions in the public sector Dr Paul Strengers Executive Director International Plasma Fractionation Association ISdS and IFBDO Conference Be
More informationEssential Skills Course Acute Care Module. Respiratory Day 2 (Arterial Blood Gases) Pre course Workbook
Essential Skills Course Acute Care Module Respiratory Day 2 (Arterial Blood Gases) Pre course Workbook Acknowledgements This pre course workbook has been complied and updated with reference to the original
More informationHypothermia, the Diving Reflex, and Survival. Briana Martin. Biology 281 Professor McMillan April 17, XXXX
CSE Paper (Martin) Hypothermia, the Diving Reflex, and Survival Full title, writer s name, name of course, instructor s name, and date (all centered). Briana Martin Biology 281 Professor McMillan April
More informationSchistosomiasis. World Health Day 2014 SMALL BITE: Fact sheet. Key facts
Fact sheet Key facts is an acute and chronic disease caused by parasitic worms. At least 249 million people required preventive treatment for schistosomiasis in 2012. The number of people reported to have
More informationHaldol lactate vs haldol decanoate
Haldol lactate vs haldol decanoate The Borg System is 100 % Haldol lactate vs haldol decanoate Medscape - Indication-specific dosing for Haldol, Haldol Decanoate (haloperidol), frequency-based adverse
More informationWhy we should care (I)
What the $*!# is Lung Protective Ventilation and Why Should I be Using it in the OR? Disclosures KATHERINE PALMIERI, MD, MBA 64 TH ANNUAL POSTGRADUATE SYMPOSIUM UNIVERSITY OF KANSAS MEDICAL CENTER DEPARTMENT
More informationpopulation Completed double-blind 458 (67.7) 445 (65.0) study n (%)
Study No: ARIA3002 Year 4 Title: A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationSUPPLEMENTARY APPENDIX. Ary Serpa Neto MD MSc, Fabienne D Simonis MD, Carmen SV Barbas MD PhD, Michelle Biehl MD, Rogier M Determann MD PhD, Jonathan
1 LUNG PROTECTIVE VENTILATION WITH LOW TIDAL VOLUMES AND THE OCCURRENCE OF PULMONARY COMPLICATIONS IN PATIENTS WITHOUT ARDS: a systematic review and individual patient data metaanalysis SUPPLEMENTARY APPENDIX
More information